25 February 2020

The cervical screening program was established to identify increased risk of cervical cancer in women aged between 30 and 60 years. Cervical cancer is caused by a long-term virus infection: the human papillomavirus (HPV). Early detection of HPV can prevent cervical cancer. The Biobank BVO contains left-over cytological material from the cervical screening program. The ambition of the BVO Biobank is to make this residual material available for scientific research to optimize the current cervical cancer screening program. Moreover, it aims to create a more personalized intervention by promoting better understanding of the oncogenic progression and transformation of high-risk HPV (hrHPV) infected cells and the identification/testing of biomarkers or biomarker profiles.
 
  • Want to know more about these subjects? Click on the buttons below for more news.

    Radboud Biobank

Related news items


Control over Human Biomaterials Act [Wet zeggenschap lichaamsmateriaal] (Wzl)

19 July 2022

The Ministry of Health, Welfare and Sport (VWS) is currently preparing a Control over Human Biomaterials Act [Wet zeggenschap lichaamsmateriaal] (Wzl) which will serve in the future as a specific legal framework for the (further) use of body tissue for medical scientific research.

read more

Health-RI annual report

19 July 2022

Health-RI has presented the 2021 annual report. In this report they outline an overview of recent activities and results of the past year 2021 (in Dutch).

read more

SPIDI sub-biobank

19 July 2022

The SPIDI collection aims to assess the prognostic value of MRI-DWI (new form of MRI research) and biomarkers (brain-specific proteins in cerebrospinal fluid) in the first 24 hours after the occurrence of a spinal cord injury as a result of trauma.

read more

MyCoS sub-biobank

8 April 2022 The Radboud Biobank has added one new sub-biobank to the collection: MyCoS. read more